• Unlocking Drug Discovery with DiscoveryProbe Natural Product

  2026-06-16

  DiscoveryProbe Natural Product Library Plus empowers researchers with a broad, cell-permeable compound selection, ready for high-throughput screening. Its rigorously validated, DMSO pre-dissolved plates accelerate hit identification, especially for challenging targets like protozoan enzymes.

• Wnt Agonist 1 (BML-284): Precision Tools for Wnt Pathway Res

  2026-06-16

  Wnt agonist 1 (BML-284) enables reproducible, high-fidelity activation of the canonical Wnt signaling pathway for studies in cell differentiation, developmental biology, and chemoresistance. This guide details evidence-backed experimental workflows, optimization strategies, and troubleshooting tips, making it an essential resource for advanced Wnt pathway cellular differentiation research.

• Triacetin (Glyceryl Triacetate): Metabolic Modulation & Rese

  2026-06-15

  Explore the unique metabolic potential of Triacetin (glyceryl triacetate) in biochemical research, focusing on its role as a metabolic modulator and its implications for advanced life science assays. This article delivers new insights and practical protocols grounded in recent scientific breakthroughs.

• SAR131675: Precision VEGFR-3 Inhibition in Angiogenesis Rese

  2026-06-15

  SAR131675 delivers unmatched selectivity as a VEGFR-3 inhibitor, empowering researchers to dissect lymphangiogenesis and tumor progression with high fidelity. This article offers protocol enhancements, troubleshooting insights, and a translational bridge from nicotine-driven CKD research to vascular targeting strategies.

• Carbapenemase Genes in CREC: Transmission Dynamics in Guangd

  2026-06-14

  This study provides a comprehensive genomic and epidemiological characterization of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong, China. Key innovations include mapping the prevalence, genetic context, and horizontal transfer rates of blaNDM-1 and other resistance determinants during the COVID-19 pandemic, informing both molecular surveillance and experimental approaches to multidrug resistance.

• Distinct Metrics for Evaluating Cancer Drug Effects In Vitro

  2026-06-13

  Schwartz's dissertation introduces a rigorous distinction between proliferative arrest and cell death when assessing in vitro drug responses in cancer models. This approach clarifies the interpretation of anti-cancer compound efficacy and offers pathways for improved assay design in translational research.

• Standardized Whole-Blood Stimulation Reveals Metabolic Contr

  2026-06-12

  The reference study establishes a reproducible protocol for analyzing immune responses in human whole blood under metabolic modulation, with a focus on standardized workflows and robust cytokine profiling. This approach enables precise interrogation of how metabolic inhibitors, such as those blocking fatty acid oxidation, selectively shape immune cell function and cytokine output, supporting translational immunometabolism research.

• Gastrin I (human): Advancing Precision in Gastric Acid Model

  2026-06-12

  Explore how human Gastrin I peptide empowers next-generation gastric acid secretion pathway research through mechanistic insight, advanced organoid models, and improved translational relevance. This in-depth analysis uniquely bridges molecular pharmacology and innovative in vitro systems.

• Cytochalasin D in Applied Actin Polymerization Inhibition Wo

  2026-06-11

  Cytochalasin D stands out as a benchmark actin polymerization inhibitor for dissecting cytoskeletal dynamics, cell cycle arrest, and advanced nanoparticle uptake mechanisms. This article details optimized workflows, troubleshooting guidance, and cross-domain insights—bridging cancer, virology, and ocular drug delivery research.

• Sodium Orthovanadate: Phosphorylation State Preservation in

  2026-06-11

  Sodium Orthovanadate (Na3VO4) is the gold standard for reversible, high-fidelity inhibition of phosphatases, empowering robust preservation of protein phosphorylation in kinase, metabolic, and insulin signaling assays. Its competitive, EDTA-reversible mechanism makes it indispensable for sensitive workflows where signal integrity and reproducibility are paramount.

• LY2228820: Dual-Action p38 MAPK Inhibitor for Advanced Resea

  2026-06-10

  Explore how LY2228820, a potent p38 MAP kinase inhibitor, enables dual-action control of phosphorylation and dephosphorylation in inflammation and cancer research. This article reveals new assay design strategies, integrating mechanistic insights beyond conventional inhibitor reviews.

• (-)-Arctigenin as a MEK1 Inhibitor: Advanced Workflows & Ins

  2026-06-10

  Leverage (-)-Arctigenin’s unique dual action as a MEK1 inhibitor and iNOS expression blocker for precise breast cancer and inflammation research. This guide translates the latest pathway-driven findings into actionable protocols and troubleshooting strategies, empowering researchers to accelerate discovery in tumor microenvironment modeling.

• Torin2 in Apoptosis Assays: Unraveling mTOR and RNA Pol II I

  2026-06-09

  Explore how Torin2, a potent mTOR inhibitor, enables advanced dissection of apoptosis mechanisms beyond transcriptional repression. This article uniquely integrates structural binding insights and RNA Pol II-driven cell death for next-level cancer research assays.

• hiPSC-Derived Intestinal Organoids: A New Standard for Pharm

  2026-06-09

  This study establishes an efficient protocol for generating human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) as advanced in vitro models for pharmacokinetic research. The findings reveal that hiPSC-IOs recapitulate key metabolic and transporter functions of the human intestinal epithelium, addressing limitations of traditional models and enabling more predictive drug absorption studies.

• RITA (NSC 652287): A New Frontier for Translational Cancer R

  2026-06-08

  This article offers a strategic, mechanistic exploration of RITA (NSC 652287) for translational oncology. It bridges advanced p53-targeted approaches, in vitro assay design, and the evolving landscape of renal carcinoma research, referencing both recent methodological breakthroughs and robust in vivo evidence. Key protocol parameters and critical insights for researchers seeking next-generation apoptosis assays and tumor xenograft models are featured.

14544 records 1/970 page Next 12345 下5页 Last page